Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 is a new type of coronavirus that can cause Coronavirus Disease 2019 (Covid-19) and is associated with an increased risk of thrombosis-related pulmonary embolism. Globally, doctors have revised their management strategies for suspected and confirmed PD in patients with Coronavirus disease (Covid-19) in 2019. Choosing the right drug and the right dose requires consideration of potential comorbidities, which can be explained by the direct and indirect pathological consequences of Covid-19, complement activation, cytokine release, endothelial dysfunction, and the interaction between different types of blood cells. Discuss the pathophysiological events, therapeutic mortality strategies, risk factors and clinical management of patients with Covid-19 pulmonary embolism.
Highlights
SARSCoV2 appears to use angiotensinconverting enzyme receptor 2 to enter lung cells [1]
Patients with severe pneumonia caused by Covid-19 can cause sepsis and can induce the release of inflammatory cytokines, which can promote the activation of hypercoagulable state [4]
The prevalence of pulmonary embolism is frequently reported in Covid-19 and is often seen in Covid-19 patients without other standard risk factors, indicating that it is an independent risk factor for VTE [7]
Summary
SARSCoV2 appears to use angiotensinconverting enzyme receptor 2 to enter lung cells [1]. Due to the lack of large-scale prospective studies in this area, little is known about the epidemiology and pathophysiological mechanisms of Covid-19related PD. Understanding these aspects is essential for the early diagnosis and proper management of this potentially fatal complication. It is reported that despite thrombosis prevention, severely ill patients with Covid-19 still develop PD, questioning the possible effect of implementing higher thrombosis prevention doses than used in standard practice [9]. The current literature on this topic defines the epidemiology, possible underlying pathophysiological mechanisms, mortality, risk factors, and therapeutic importance of Covid-19related PD
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
